Q-omics provides the consensus-scored SLC25A44 profile across patient tissues and cancer cell-line models. SLC25A44 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC25A44 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SLC25A44 RNA expression shows 20,207 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where SLC25A44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A44 survival associations across molecular data types. SLC25A44 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A44 RNA expression–survival associations across cancer types. High SLC25A44 expression shows unfavorable associations in ACC, MESO, KICH and UCEC, but favorable associations in KIRC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC25A44 RNA expression.
This table summarizes SLC25A44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A44 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, BRCA and STAD. The HNSC box plot shows higher SLC25A44 RNA expression in tumor versus normal tissue (log2 FC = +0.843, t-test p < 0.001).
This table shows molecular features associated with SLC25A44 in patient tissues and cancer cell lines. In patient samples, SLC25A44 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
